Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Rosen

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Tobacco Control|March 4, 2022
Plain tobacco packaging: progress, challenges, learning and opportunitiesCrawford Moodie, Janet Hoek, David Hammond, et al.
Pediatrics|January 3, 2018
Protecting Young Children From Tobacco Smoke Exposure: A Pilot Study of Project Zero ExposureLaura Rosen, Nurit Guttman, Vicki Myers, et al.
Health Research Policy and Systems|May 29, 2010
A framework for developing an evidence-based, comprehensive tobacco control programLaura Rosen, Elliot Rosenberg, Martin McKee, et al.
British Journal of Clinical Pharmacology|May 15, 2021
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1AWei Yin, Dimitrios Arkilo, Polyna Khudyakov, et al.
Journal of Clinical Pharmacology|July 1, 2006
Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizersSusie Xiujiang Li, Edward Pequignot, Deborah Panebianco, et al.
Journal of Alzheimer'S Disease : JAD|October 22, 2016
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's DiseaseGvido Cebers, Robert C Alexander, Samantha Budd Haeberlein, et al.
Journal of Sleep Research|March 19, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individualsRebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Sleep|February 2, 2013
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy menHong Sun, William P Kennedy, Darren Wilbraham, et al.
Psychopharmacology|August 15, 2025
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trialPeter C T Hawkins, Adam J Schwarz, James M Stone, et al.
Translational Psychiatry|May 28, 2021
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulationPatricio O'Donnell, Francis M Dijkstra, Ugur Damar, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Tobacco Control|March 4, 2022
Plain tobacco packaging: progress, challenges, learning and opportunitiesCrawford Moodie, Janet Hoek, David Hammond, et al.
Pediatrics|January 3, 2018
Protecting Young Children From Tobacco Smoke Exposure: A Pilot Study of Project Zero ExposureLaura Rosen, Nurit Guttman, Vicki Myers, et al.
Health Research Policy and Systems|May 29, 2010
A framework for developing an evidence-based, comprehensive tobacco control programLaura Rosen, Elliot Rosenberg, Martin McKee, et al.
British Journal of Clinical Pharmacology|May 15, 2021
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1AWei Yin, Dimitrios Arkilo, Polyna Khudyakov, et al.
Journal of Clinical Pharmacology|July 1, 2006
Lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizersSusie Xiujiang Li, Edward Pequignot, Deborah Panebianco, et al.
Journal of Alzheimer'S Disease : JAD|October 22, 2016
AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's DiseaseGvido Cebers, Robert C Alexander, Samantha Budd Haeberlein, et al.
Journal of Sleep Research|March 19, 2023
Orexin 2 receptor-selective agonist danavorexton (TAK-925) promotes wakefulness in non-human primates and healthy individualsRebecca Evans, Haruhide Kimura, Masato Nakashima, et al.
Sleep|February 2, 2013
Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy menHong Sun, William P Kennedy, Darren Wilbraham, et al.
Psychopharmacology|August 15, 2025
The GPR139 agonist TAK-041 produces time-dependent alterations to cerebral blood flow and reward system function in patients with schizophrenia: a randomised placebo-controlled trialPeter C T Hawkins, Adam J Schwarz, James M Stone, et al.
Translational Psychiatry|May 28, 2021
Transcranial magnetic stimulation as a translational biomarker for AMPA receptor modulationPatricio O'Donnell, Francis M Dijkstra, Ugur Damar, et al.
Pageof 5